129 related articles for article (PubMed ID: 3954731)
21. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
22. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
23. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization.
Laub R; Schneider YJ; Octave JN; Trouet A; Crichton RR
Biochem Pharmacol; 1985 Apr; 34(8):1175-83. PubMed ID: 3994740
[TBL] [Abstract][Full Text] [Related]
24. Mobilization of iron from ferritin by isolated mitochondria. Effects of species compatibility between ferritin and mitochondria and iron content of ferritin.
Ulvik RJ; Romslo I; Roland F; Crichton RR
Biochim Biophys Acta; 1981 Sep; 677(1):50-6. PubMed ID: 7295789
[TBL] [Abstract][Full Text] [Related]
25. The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.
Kontoghiorghes GJ
Biochim Biophys Acta; 1986 Jan; 869(2):141-6. PubMed ID: 3942757
[TBL] [Abstract][Full Text] [Related]
26. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Ibrahim AS; Spellberg B; Edwards J
Curr Opin Infect Dis; 2008 Dec; 21(6):620-5. PubMed ID: 18978530
[TBL] [Abstract][Full Text] [Related]
27. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
28. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
29. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
[TBL] [Abstract][Full Text] [Related]
30. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
31. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
32. In vivo iron mobilisation evaluation of hydroxypyridinones in 59Fe-ferritin-loaded rat model.
Liu ZD; Lu SL; Hider RC
Biochem Pharmacol; 1999 Mar; 57(5):559-66. PubMed ID: 9952320
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.
Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS
J Infect Dis; 2000 Feb; 181(2):484-90. PubMed ID: 10669330
[TBL] [Abstract][Full Text] [Related]
34. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome.
De Domenico I; Vaughn MB; Li L; Bagley D; Musci G; Ward DM; Kaplan J
EMBO J; 2006 Nov; 25(22):5396-404. PubMed ID: 17082767
[TBL] [Abstract][Full Text] [Related]
35. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin.
Bridges KR; Hoffman KE
J Biol Chem; 1986 Oct; 261(30):14273-7. PubMed ID: 3464594
[TBL] [Abstract][Full Text] [Related]
36. Mobilization of ferritin iron by chelators in vitro [proceedings].
Roman F; Roland F; Crichton RR
Arch Int Physiol Biochim; 1979 Aug; 87(3):635-6. PubMed ID: 93465
[No Abstract] [Full Text] [Related]
37. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
38. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
Fernández-Martín JL; Menéndez-Fraga P; Canteros MA; Díaz-López JB; Cannata-Andía JB
Clin Chim Acta; 1994 Oct; 230(2):137-45. PubMed ID: 7834865
[TBL] [Abstract][Full Text] [Related]
39. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Neupane GP; Kim DM
Transfusion; 2009 Aug; 49(8):1762-9. PubMed ID: 19413741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
